MX2015003564A - Composiciones y metodos de uso de un compuesto de control de inapetencia. - Google Patents

Composiciones y metodos de uso de un compuesto de control de inapetencia.

Info

Publication number
MX2015003564A
MX2015003564A MX2015003564A MX2015003564A MX2015003564A MX 2015003564 A MX2015003564 A MX 2015003564A MX 2015003564 A MX2015003564 A MX 2015003564A MX 2015003564 A MX2015003564 A MX 2015003564A MX 2015003564 A MX2015003564 A MX 2015003564A
Authority
MX
Mexico
Prior art keywords
inappetance
livestock
compositions
methods
controlling compound
Prior art date
Application number
MX2015003564A
Other languages
English (en)
Inventor
Bill Zollers
Linda Rhodes
Ernst Heinen
Gopinath Devaraj
Original Assignee
Aratana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aratana Therapeutics Inc filed Critical Aratana Therapeutics Inc
Publication of MX2015003564A publication Critical patent/MX2015003564A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

La invención proporciona un método para tratar la pérdida de peso inducida por inapetencia en uno o varios animales de compañia o ganado. El método proporciona la administración de una cantidad terapéuticamente eficaz de una composición que contiene capromorelina al animal de compañía o ganado. Opcionalmente, uno o varios agentes aromáticos o agentes que enmascaran el sabor se pueden añadir a la composición que contiene capromorelina para realzar o enmascarar el condimento de la composición para el animal de compañía o ganado.
MX2015003564A 2012-09-27 2013-09-27 Composiciones y metodos de uso de un compuesto de control de inapetencia. MX2015003564A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261706164P 2012-09-27 2012-09-27
PCT/US2013/062227 WO2014052780A2 (en) 2012-09-27 2013-09-27 Compositions and methods of use of an inappetance-controlling compound

Publications (1)

Publication Number Publication Date
MX2015003564A true MX2015003564A (es) 2015-11-16

Family

ID=50339468

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003564A MX2015003564A (es) 2012-09-27 2013-09-27 Composiciones y metodos de uso de un compuesto de control de inapetencia.
MX2022015141A MX2022015141A (es) 2012-09-27 2015-03-19 Composiciones y metodos de uso de un compuesto de control de inapetencia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015141A MX2022015141A (es) 2012-09-27 2015-03-19 Composiciones y metodos de uso de un compuesto de control de inapetencia.

Country Status (18)

Country Link
US (1) US11090292B2 (es)
EP (3) EP4302825A2 (es)
JP (2) JP6779618B2 (es)
KR (5) KR20150058345A (es)
CN (2) CN105072909A (es)
AR (2) AR092713A1 (es)
AU (2) AU2013323349B2 (es)
BR (1) BR112015006282B1 (es)
CA (1) CA2886091C (es)
DK (1) DK3524260T3 (es)
ES (1) ES2959427T3 (es)
MX (2) MX2015003564A (es)
NZ (2) NZ707174A (es)
PL (1) PL3524260T3 (es)
PT (1) PT3524260T (es)
RU (1) RU2648958C2 (es)
TW (3) TW202106298A (es)
WO (1) WO2014052780A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762564B (zh) 2010-02-26 2015-09-30 拉夸里亚创药株式会社 用于治疗恶病质的葛瑞林受体激动剂
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
ES2959427T3 (es) 2012-09-27 2024-02-26 Elanco Animal Health Incorporated Composiciones farmacéuticas para el tratamiento de la inapetencia
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
RU2680410C1 (ru) * 2015-01-28 2019-02-21 Аратана Терапьютикс, Инк. Композиции и способы длительного применения соединения для прироста массы тела
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
JP7105232B2 (ja) * 2016-11-11 2022-07-22 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド ペットフードの組成物及び方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US193273A (en) * 1877-07-17 Improvement in material for pulley-covers
JP2893901B2 (ja) * 1990-09-07 1999-05-24 株式会社岐阜免疫研究所 動物用抗体含有油性ペースト製剤
CA2095786A1 (en) 1992-05-08 1993-11-09 Franco J. Vaccarino Method of stimulating appetite
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
EP1181933A3 (en) 2000-06-29 2002-04-10 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating or increasing appetite
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
EP1742655A2 (en) * 2004-04-07 2007-01-17 Gastrotech Pharma A/S Use of ghrelin for the treatment of hyperthyroidism
WO2006045313A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of secretagogues for treatment of organ transplant patients
EP1956923A1 (en) 2005-11-02 2008-08-20 Nestec S.A. Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use
CA2645844C (en) * 2006-03-13 2016-04-26 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
RU2459831C2 (ru) 2006-09-27 2012-08-27 Ипсен Фарма С.А.С. Аналоги грелина с замещением на n-конце
JP2008127377A (ja) * 2006-11-24 2008-06-05 Jichi Medical Univ Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
US20080226802A1 (en) * 2007-03-14 2008-09-18 Concentrate Manufacturing Company Of Ireland Beverage having natural sweeteners with one or more stevia components and source of berry
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
RU2007129408A (ru) * 2007-07-31 2009-02-10 Игорь Николаевич Жирков (RU) Способ выращивания поросят в период откорма
FR2920295B1 (fr) * 2007-09-05 2009-12-11 Desvac Dispositif d'injection de produits veterinaires a des volailles, comprenant un element de contention presentant une forme anatomique incluant des moyens de calage d'un os reperable
EP2215914B1 (en) * 2007-11-12 2013-04-24 San-Ei Gen F.F.I., INC. Method of improving sweetness qualities of stevia extract
JP5552481B2 (ja) 2009-03-26 2014-07-16 武田薬品工業株式会社 ピラゾール化合物
CN102762564B (zh) * 2010-02-26 2015-09-30 拉夸里亚创药株式会社 用于治疗恶病质的葛瑞林受体激动剂
ES2959427T3 (es) 2012-09-27 2024-02-26 Elanco Animal Health Incorporated Composiciones farmacéuticas para el tratamiento de la inapetencia

Also Published As

Publication number Publication date
JP6779618B2 (ja) 2020-11-04
BR112015006282B1 (pt) 2021-11-23
AU2013323349B2 (en) 2016-09-15
CN105072909A (zh) 2015-11-18
NZ707174A (en) 2018-10-26
AU2016216741A1 (en) 2016-09-15
TWI732158B (zh) 2021-07-01
EP2906041A4 (en) 2016-10-26
EP3524260B1 (en) 2023-09-13
US11090292B2 (en) 2021-08-17
EP3524260A1 (en) 2019-08-14
AU2016216741B2 (en) 2018-02-15
RU2015114996A (ru) 2016-11-20
TW201924680A (zh) 2019-07-01
KR20230097201A (ko) 2023-06-30
BR112015006282A2 (pt) 2017-07-04
KR20190143484A (ko) 2019-12-30
CA2886091A1 (en) 2014-04-03
AR123902A2 (es) 2023-01-25
WO2014052780A3 (en) 2014-06-26
KR20150058345A (ko) 2015-05-28
CA2886091C (en) 2021-11-30
KR20220003640A (ko) 2022-01-10
DK3524260T3 (da) 2023-10-09
CN111419845A (zh) 2020-07-17
JP6796097B2 (ja) 2020-12-02
JP2018117625A (ja) 2018-08-02
EP2906041A2 (en) 2015-08-19
TW201417812A (zh) 2014-05-16
PT3524260T (pt) 2023-10-13
MX2022015141A (es) 2023-02-01
TWI667024B (zh) 2019-08-01
RU2648958C2 (ru) 2018-03-28
TW202106298A (zh) 2021-02-16
AU2013323349A1 (en) 2015-05-07
ES2959427T3 (es) 2024-02-26
US20140088139A1 (en) 2014-03-27
NZ746394A (en) 2019-01-25
JP2016500660A (ja) 2016-01-14
PL3524260T3 (pl) 2023-11-27
KR20210009438A (ko) 2021-01-26
AR092713A1 (es) 2015-04-29
EP4302825A2 (en) 2024-01-10
WO2014052780A2 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
MX2022015141A (es) Composiciones y metodos de uso de un compuesto de control de inapetencia.
MX2021015234A (es) Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA201500923A1 (ru) Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
EA201290919A1 (ru) Индазольные соединения и их применение
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
EA201590880A1 (ru) Композиции и способы лечения протеинопатий
NZ708453A (en) Germicidal compositions comprising carboxylic acid mixture and use as topical disinfectants
PH12014502864A1 (en) Pharmaceutical compositions and treatment of mastitis
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
NZ706990A (en) A veterinary method of alleviating noise aversion
MX2019006773A (es) Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros.
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2015005734A (es) Metodos de tratamiento de enfermedades hepaticas.
MX2013013098A (es) Metodos y composiciones para fomentar el crecimiento de la masa corporal magra.
NZ733658A (en) Compositions and methods for chronic use of a weight-gaining compound
MX2017007856A (es) Composicion para el cuidado bucal.
MY197404A (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
IN2015DN00735A (es)
MX2014008194A (es) Cefovecina util en el tratamiento de la enfermedad de lyme.
MX2013012990A (es) Metodos y composiciones para preservar la masa corporal magra durante la perdida de peso.
NZ701190A (en) Combination meloxicam and xylazine therapy in animals

Legal Events

Date Code Title Description
FG Grant or registration